Showing posts with label dementia articles. Show all posts
Showing posts with label dementia articles. Show all posts

Sunday, September 6, 2009

Moderate drinkers '25% less likely to develop dementia'

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Craegimoor.co.uk

According to the latest research, light to moderate drinkers are 25 per cent less likely to develop dementia than those who do not drink any alcohol.

Research studies, based on a survey of 10,000 people worldwide, explored links between drinking and dementia through meta-analysis of 15 research studies.

Results of studies were followed up with participants at intervals over two to eight years, according to study leader Kaarin Anstey, of the Australian National University.

"We found that light to moderate drinkers were 28 per cent less likely to develop Alzheimer's than non-drinkers, 25 per cent less likely to develop vascular dementia, and 26 per cent less likely to develop any dementia'," Ms Anstey said.

The report was published in the American Journal of Geriatric Psychiatry.

Some of the research projects considered in the ANU synthesis study only reported whether participants were drinkers or non-drinkers and did not explore the extent of their drinking.

The news comes as research carried out by the Norwegian University of Science and Technology found that people who do not drink alcohol have an increased risk of anxiety and depression.

Saturday, September 5, 2009

Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid-Beta...

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits
Amyloid-Beta Accumulation, a Hallmark of Alzheimer's Disease
- Results of Laboratory Study Detecting Previously Unidentified Bioactives in
Standardized Turmeric Extract Will Be Published in Upcoming Issue of Current
Alzheimer's Research -




NAPLES, Fla., Sept. 3 /PRNewswire/ -- Alzheimer's disease is the most common
cause of dementia among the elderly and is projected to increase in prevalence
over the next decades as the population ages -- creating an urgent need for
treatments that will prevent or reverse the now-inexorable course of cognitive
deterioration and memory loss. Because development of synthetic drugs is
expensive and complex, many researchers are focusing on botanical extracts
whose benefits have been documented by traditional medicine systems. In that
vein, scientists with HerbalScience Group LLC, working with researchers from
other organizations and medical institutions, conducted an in-depth study of
optimized turmeric extracts, demonstrating that key bioactives in the
botanical extracts inhibit aggregation and release of amyloid, a protein
fragment considered a prime causal suspect in Alzheimer's disease.

An article detailing the study, titled "Optimized Turmeric Extracts Have
Potent Anti-Amyloidogenic Effects," will be published in the December 2009
issue of Current Alzheimer's Research, a peer-reviewed scientific journal. The
authors are affiliated with several research organizations and medical
institutions, including HerbalScience Group LLC; the University of Miami
Leonard M. Miller School of Medicine, Miami, Florida; the University of South
Florida College of Medicine, Tampa, Florida; Veterans Administration Hospital,
Research Service, Tampa, Florida; and Natura Therapeutics, Tampa, Florida.

"The optimized extracts outperformed curcumin, the best studied anti-Alzheimer
extract from turmeric," said Randall S. Alberte, Ph.D., one of the authors of
the study and Chief Scientific Officer of HerbalScience Group LLC, a Naples,
Florida, and Singapore-based company dedicated to applying advanced science
and technology to the production of botanical drugs and nutraceuticals.

For the research, three standardized turmeric extracts were prepared that were
enriched in curcuminoids and turmerones, two major classes of compounds
present in turmeric. Each of the three proprietary extracts had a different
chemical profile and was standardized using advanced extraction technology
developed by HerbalScience to create herbal extracts that are dose-reliable
and efficacious. The activities of the extracts were compared to standard
curcuminoids.

Inhibition of amyloid aggregation and secretion was studied in vitro among the
different extracts and standards, and it was found that one of the extracts
had the greatest activity in inhibiting the aggregation and secretion of
amyloid. This extract, containing the highest levels of curcuminoids among all
of the extracts, demonstrated activity that was significantly greater than
curcumin alone, the most active of the four curcuminoid standards. This result
indicates that an enriched turmeric extract could be just as or more effective
than curcumin, the most commonly studied turmeric material for Alzheimer's
disease.

The HerbalScience study also used advanced DART (Direct Analysis in Real Time)
Time-of-Flight mass spectrometry technology to generate detailed chemical
profiles of each extract in order to determine the key bioactive compounds.
Only 5% of the compounds were known chemicals, with the remaining 95% being
identified for the first time. With further chemical analysis and
identification of key bioactives, highly standardized extracts such as these
could offer a rich new source for potential drug discovery for Alzheimer's and
other therapeutic targets.

The journal article detailing the study will appear in the December 2009 issue
of Current Alzheimer's Research (Vol. 6, No. 6). Authors are R. Douglas
Shytle, Paula C. Bickford, Kavon Rezai-zadeh, L Hou, Jin Zeng, Jun Tan, and
Paul Sanberg, with University of South Florida College of Medicine
affiliations including the Department of Neurosurgery Center for Excellence in
Aging and Brain Repair, Department of Psychiatry and Behavioral Medicine
Silver Child Development Center, and Neuroscience Program; Cyndy D. Sanberg of
Natura Therapeutics, Inc., Tampa, Florida; Bill Roschek Jr. and Randall S.
Alberte, of HerbalScience Group LLC, Naples, Florida; and Ryan C. Fink,
Department of Biochemistry and Molecular Biology, The University of Miami
Leonard M. Miller School of Medicine, Miami, Florida. Dr. Bickford is also
affiliated with the Veterans Administration Hospital, Research Service, Tampa,
Florida; and Drs. Shytle, Bickford, Tan, and Paul Sanberg are also affiliated
with Natura Therapeutics.

HerbalScience is a privately-held life sciences company headquartered in
Naples, Florida, with facilities in Singapore. HerbalScience is engaged in the
discovery, development, manufacture, and marketing of proprietary botanical
compounds for human health in the U.S. and international markets. The company
has prominent alliances with prestigious university laboratories and prominent
researchers in the U.S., as well as research institutions in China.

Wednesday, September 2, 2009

Why Alzheimer's and Other Dementia Caregivers Should Be Honored This Labor Day

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Healthnews-stat.com

It is estimated that there are over 55 million caregivers, of people with Alzheimer's disease and related dementias, worldwide. Learn what a hard job they have and why they deserve everyone's praise

According to the United States government Labor Day, celebrates the contributions workers have made to the strength, prosperity, and well-being of America. Alzheimer's and other dementia caregivers certainly meet these criteria.

The first reason to honor these caregivers is for the financial burden they incur when caring for a person with dementia. First the family has consulted an Elder law attorney to get all the finances in order. Most likely the caregiver had to cut back on the hours of paid employment. Despite using all the resources out there, all expenses for the care of a dementia person will not be covered. That means go without, or pay for necessary items out of pocket.

The second reason to pay tribute to ones caring for someone with dementia is their resourcefulness. Caregivers are good at coming up with unique strategies for managing and paying for the supervision of their loved one. They may get help from attending a support group in person or online. However, they are the ones ultimately responsible for a workable plan of care.

Third is recognizing that many perform physically demanding aspects of a dementia persons' care. Many do the bathing, feeding and toileting of their family member with dementia. These tasks are difficult because many with dementia are confused and combative.

Next, these caregivers should be honored for all the time they devote to all aspects of a dementia persons' life. As just mentioned, most caregivers are responsible for the physical aspects of care. But they also must engage their loved one in meaningful activities throughout the day and sometimes well into the night. Fortunately many take advantage of adult day care to ease the burden. Unfortunately some dementia folks refuse to participate in or have behaviors that preclude them from attending these worthwhile programs.

The fifth reason for honoring those caring for a dementia person is all the time they devote to this job. The caregiver is most likely responsible for everything from cleaning to cooking to shopping to yard work. The list seems endless. These tasks are even more difficult because while the caregiver is doing them, he must also keep the dementia person safe.

It has also been reported recently that caregivers take longer to fall asleep despite being exhausted and that caregivers of dementia spouses enjoy life less Not to mention one-quarter of spouses of those with Alzheimer's disease and related dementias are depressed
Also according to a report published by the National Alzheimer's Association, ten million caregivers provided....read all about honoring caregivers on Labor Day

Thursday, August 13, 2009

Testing Gene Therapy to Improve Brain Function in Alzheimer’s Disease Patients

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia activities

UC San Diego Medical Center


Researchers at the Shiley-Marcos Alzheimer’s Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer’s disease (AD) called CERE-110. Previously, CERE-110 was carefully studied in animals as well as in a small study to assess safety in humans. These studies showed that CERE-110 can safely induce long-term production of a natural brain cell-survival molecule called Nerve Growth Factor (NGF) in the brains of AD patients.

Researchers at 12 U.S. sites, including the Shiley-Marcos Alzheimer’s Disease Research Center at the University of California San Diego are now seeking 50 study participants with mild to moderate AD for the Phase 2 clinical study. The experimental treatment utilizes viral-based gene transfer. Brain cells that receive gene transfer will, in turn, make NGF, a naturally occurring protein that maintains nerve cell function and survival in the brain.

“NGF is known to support the survival and function of the neurons that deteriorate in Alzheimer’s disease,” said Michael Rafii, MD, PhD, assistant professor in the UC San Diego Department of Neurosciences. “These neurons produce a chemical called acetylcholine, which is important in memory and cognitive function. The hope is that restoration of this system’s function may improve memory in Alzheimer’s patients.” AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans. That number is expected to soar to more than 11 million by 2040.

In the trial, a neurosurgeon will inject CERE-110 directly into the nucleus basalis of Meynert (NBM) of the brain, an area where neuron death occurs in AD. The brain cells contained in this nucleus, located deep within the brain, form the cholinergic system. The cholinergic system uses acetylcholine in transmitting nerve impulses involved in memory and cognition, and these cells are known to profoundly degenerate in the course of Alzheimer’s disease. Researchers hope that exposing these cells to NGF may preserve function and prevent further cell loss and potentially slow intellectual decline seen in Alzheimer’s patients.

Previous Research

A Phase 1 study was conducted at Rush University in Chicago and the University of California San Diego, where the treatment was found to be generally safe and well-tolerated. The 10 subjects with AD underwent cognitive testing, measures of activities of daily living, and MRI and PET (positron emission tomography) scans. When compared to other severity-matched individuals with AD, researchers observed increases in brain metabolism in several cortical regions of the brain in some of the trial participants at six months and 12 months, suggesting a potential reversal of patterns typically observed in AD. In addition, in follow up ranging from six months to more than four years post-treatment, there have been no side effects thought to be caused by CERE-110.

In previous animal studies, CERE-110....read all of Testing Gene Therapy to Improve Brain Function in Alzheimer’s Disease Patients

Friday, August 7, 2009

Work protects against dementia

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

BBCTurkish.com

A new study in the International Journal of Geriatric Psychiatry suggests that carrying on working into old age, rather than occupation or education, can help protect against dementia.

The study looked at nearly 400 men who developed Alzheimer's disease. It assessed the time they spent in full-time education, the type of work they did and the point at which they retired.

The researchers detected no link between the onset of dementia and education or occupation. But they found that every extra year at work was associated with a six week delay in Alzheimer's. They say this points to the value of keeping the brain active by working.

They also acknowledge that the nature of retirement is changing, and for some people it may be as intellectually stimulating as working. The Alzheimer's Research Trust, which funded the study, says more people than ever retire later in life to avert financial hardship, but there may be a silver lining: lower dementia risk. However it says much more research is needed in order to understand how to delay or prevent dementia.

Tuesday, August 4, 2009

Dementia induced and blocked in Parkinson's fly model

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

EurekAlert

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine


St. Louis,
Parkinson's disease is well-known for impairing movement and causing tremors, but many patients also develop other serious problems, including sleep disturbances and significant losses in cognitive function known as dementia.

Now researchers at Washington University School of Medicine in St. Louis have modeled Parkinson's-associated dementia for the first time. Scientists showed that a single night of sleep loss in genetically altered fruit flies caused long-lasting disruptions in the flies' cognitive abilities comparable to aspects of Parkinson's-associated dementia. They then blocked this effect by feeding the flies large doses of the spice curcumin.

"Clinical trials of curcumin to reduce risk of Parkinson's disease are a future possibility, but for now we are using the flies to learn how curcumin works," says author James Galvin, M.D., a Washington University associate professor of neurology who treats patients at Barnes-Jewish Hospital. "This should help us find other compounds that can mimic curcumin's protective effects but are more specific."

Galvin and senior author Paul Shaw, Ph.D., assistant professor of neurobiology, publish their results in the journal Sleep on Aug. 1.

Galvin is an expert in cognitive impairments in human Parkinson's disease; Shaw studies sleep and the brain in fruit flies. The researchers decided collaborate based in part on evidence that increased sleep loss in Parkinson's patients can precede or coincide with increased severity in other Parkinsonian symptoms.

More than 74 percent of Parkinson's patients have trouble sleeping, and up to 80 percent of patients 65 and older who have Parkinson's disease for seven years will develop dementia, according to Galvin.

Shaw's lab has linked sleep loss to changes in the dopaminergic system of the brain, the part of the brain that produces the neurotransmitter dopamine and is at the center of the damage caused by Parkinson's.

"In healthy flies, sleep deprivation......read all of Dementia induced and blocked in Parkinson's fly model

Sunday, August 2, 2009

White Matter Changes Could Predict Dementia Risk

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

redOrbit

Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

For the study, researchers followed 49 people age 65 and older who had no memory or thinking problems for an average of 9.5 years. The participants had at least three brain scans and annual tests of thinking skills. During the study, 24 of the participants developed persistent cognitive impairment, or memory problems that are a potential precursor to Alzheimer's disease or another type of dementia.

The study found that those who had theread more of White Matter Changes Could Predict Dementia Risk

Saturday, August 1, 2009

Alzheimer’s Disease: Women Affected More Often than Men

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Written by Society for Women

Nearly 5.3 million people suffer from Alzheimer’s disease (AD) in our country, and more than half of them are women, according to the National Institute on Aging in Bethesda, Md. As the general population continues to age, this number is expected to increase significantly over the next few decades.

Alzheimer’s disease is the most common form of dementia, a group of brain disorders that interferes with a person’s ability to carry out daily activities. In AD, areas of the brain change and deteriorate, which causes a decline in cognition and memory functioning. In some patients, the deficits are large enough to get in the way of performing normal, everyday tasks.

There is evidence that AD affects women differently than men. “Many studies of gender differences in cognition have pointed to greater language deficits in women with Alzheimer’s disease as compared to men,” explains Michael S. Rafii, M.D., Ph.D., director of the Memory Disorders Clinic and an attending neurologist at the Shiley-Marcos Alzheimer Disease Research Center at the University of California, San Diego.

“Naming and word-recognition skills have been reported to be more adversely affected in female patients with AD than in male patients, and the differences have been shown to be sustained over time.”

Notable sex and gender differences in behavior among Alzheimer patients have been observed as well. “Male patients exhibit greater problems than female patients in wandering, abusiveness and social impropriety, particularly in the more advanced stages of the disorder,” Rafii points out. In fact, major tranquilizers and behavior management programs are used more frequently on male patients.

While there is currently no cure for AD, researchers continue to make progress. More drugs are being studied, and researchers have identified several genes associated with the disease. “Recent work has been focused on identifying the molecule that may be causing AD symptoms,” says Rafii. Researchers from the University of Minnesota and Johns Hopkins University “discovered a protein complex in the brain that appears to impair memory.”

Combined with sophisticated imaging techniques, this discovery is enabling scientists to take a clear picture of the protein deposits in the brain. According to Rafii, “This could lead to accurate diagnosis of AD at very early stages. Previously, a definitive diagnosis of the disease could only be made through an autopsy after the patient's death, typically at a very late stage of the illness.”

Diagnosing AD can be tricky, especially because many people are under the assumption that forgetfulness is a normal part of the aging process. But patients with AD suffer from much more than simple memory lapses. Here are a few common signs and symptoms of the disease:

- Persistent forgetfulness or memory loss
- Disorientation
- Problems performing routine tasks
- Inability to express thoughts coherently or finish sentences
- Loss of judgment
- Changes in personality

As in other diseases, early diagnosis is very important for patients with AD. Certain medications have been found to be useful in the earlier stages of the disease, so the sooner the diagnosis is made, the better.

Thursday, July 30, 2009

Scientists locate disease switches

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

PSYORG.com

A team of scientists from the University of Copenhagen and the Max Planck Institute in Germany, has identified no less than 3,600 molecular switches in the human body. These switches, which regulate protein functions, may prove to be a crucial factor in human aging and the onset and treatment of diseases such as cancer, Alzheimer's disease and Parkinson's disease. The results of the team's work have been published in the current edition of the journal Science.

The team, led by Professor Matthias Mann of Novo Nordisk Center for Protein Research at the University of Copenhagen and the Max Planck Institute for Biochemistry in Germany, have detected 3,600 acetylation switches in 1,750 different proteins.

"This is more than just a technological achievement, it has also expanded the number of known acetylation switches by a factor of six, and it gives us for the first time a comprehensive insight into this type of protein modification," says Professor Mann.

A given protein can perform more than one task, and how it behaves is regulated by adding a small molecule that acts as a 'switch' which can turn on the different tasks. Acetylation is essential for cells' ability to function normally. Defective protein regulation plays a role in ageing and the development of diseases such as cancer, Parkinson's and Alzheimer's.

"With the new mapping, we can now begin to study and describe how acetylation switches respond to medications that could repair the defects on them. It can have a major impact on medical care," says Professor Mann, adding that medications to repair the damaged protein regulation are already showing promising in the treatment of cancer.

Cooperating proteins

The team also discovered that.......read all about Scientists locate disease switches

Wednesday, July 29, 2009

Large Epidemiologic Study Supports Brain Power Of Fish In Older People

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

ScienceDaily — Experts estimate that over 24 million people worldwide suffer from dementia, and many of these people live in low- and middle-income countries. Recently, there has been growing interest in whether dietary factors, particularly oily fish and meat, might influence the onset and/or severity of dementia. Oily fish are rich in omega-3 long-chain polyunsaturated fatty acids, which some studies suggest are positively related to cognitive function in later life.

Conversely, there is a suggestion from some studies that increased meat consumption may be related to cognitive decline. To examine this, a group of international researchers studied older people in 7 middle- to low-income countries. You can read the results of their study in the August 2009 issue of the American Journal of Clinical Nutrition.

Data from 14,960 participants (≥65 y of age) living in China, India, Cuba, the Dominican Republic, Venezuela, Mexico, and Peru were analyzed. Dietary habits were assessed by using standard, culturally appropriate face-to-face interviews, and dementia was diagnosed by using validated culturally and educationally fair criteria.

In each of the study countries, except India, there was an inverse association between fish consumption and dementia prevalence. These data extend to low- and middle-income countries previous conclusions from industrialized countries that increased fish consumption is associated with lower dementia prevalence in later life.

The authors propose that this....read more of how a Large Epidemiologic Study Supports Brain Power Of Fish In Older People

Monday, July 27, 2009

Hunt for Alzheimer's disease treatment intensifies

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Chicago Tribune

Drugmakers, including Abbott and Baxter, increase efforts despite setbacks

By Bruce Japsen | Tribune reporter

Just two weeks ago, word came from an international science meeting in Vienna that Abbott Laboratories had halted a study of an Alzheimer's pill, the latest in a growing number of pharmaceutical company failures related to treatment of the disease.

But the North Chicago-based medical products company and its rivals are hardly giving up.

"This is an area where the reward is so great and the unmet need is so high we are going to continue to be involved," said James Summers, head of Abbott's neuroscience drug discovery.

The payoff for treatments would be worth billions of dollars, especially as the world's population ages. The disease and related dementia affect more than 5 million Americans and 30 million people around the world. But the worldwide number is expected to rise fourfold, to 120 million people by 2050.

Abbott is competing against Deerfield-based Baxter International Inc., as well as drugmakers such as Pfizer Inc., Johnson & Johnson and Wyeth, that say they are making unprecedented investments in what has been an elusive treatment category.

"What is a positive about the increasing investments is that.......read more of
Alzheimer's disease treatment intensifies

Sunday, July 26, 2009

Pesticides May Raise Alzheimer's Risk

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

WebMD

Alzheimer's Disease Health Center

Occupational Exposure Linked to Increased Risk of Alzheimer's Disease

By Charlene Laino
WebMD Health News
Reviewed by Louise Chang, MD

(Vienna, Austria) -- Exposure to pesticides may have long-term effects on the nervous system, increasing the risk of Alzheimer’s disease in late life, a new study suggests.

Researchers say the findings support evidence of a possible link between environmental toxins and Alzheimer’s disease and may help explain why some people with risk factors for the disease get it while others do not.

“While no cause for Alzheimer’s disease has been found, [non-inherited] cases are likely due to a combination of genetic and environmental factors,” says Kathleen M. Hayden, PhD, of Duke University Medical Center in Durham, N.C.

Pesticides and Alzheimer’s
Pesticides have been proposed as a possible environmental risk factor, but there are few studies of the effects of occupational pesticides on the risk of Alzheimer’s disease, she says.

Research suggests that pesticides may affect the release of acetylcholine, a chemical that’s important for memory, Hayden tells WebMD.

Pesticide use has dramatically increased over the past 50 years, she says. There are now more than 18,000 pesticides licensed in the U.S., and more than 2 billion pounds are applied each year, Hayden says.

There are 5.3 million Americans living with Alzheimer’s disease, which disrupts memory, learning, and other mental functions. By 2010, there will be nearly half a million new cases each year and by 2050, there will be nearly a million new cases annually, according to the Alzheimer’s Association.

Working With Pesticides
The new study involved more than 4,000 residents 65 and older from an agricultural county in Utah who are participating in a larger study of risk factors for Alzheimer’s disease.

At the start of study, they were asked if they had ever been exposed to pesticides during their work and if so, which types of pesticide and for how long. Of the total, about 750 participants reported working with pesticides.

A standard test that measures overall cognitive function, including memory, attention span, and problem solving, was given at the outset and two other times over a six- to seven-year period.

The study was presented at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease.

Pesticides Linked to Alzheimer’s
After adjusting for age, sex, education, and a gene known to raise the risk of Alzheimer’s, the researchers found that people who worked with pesticides were 53% more likely to develop Alzheimer’s disease.

The study doesn’t prove that pesticides cause Alzheimer’s disease, and further research is needed, Hayden says.

The next steps are to look at whether type of pesticide and duration of use affects risk, she says.

Ralph Nixon, MD, PhD, vice chair of the Medical and Scientific Advisory Council at the Alzheimer’s Association and an Alzheimer’s expert at New York University, tells WebMD that it’s been difficult to identifyread more about Pesticides Linked to Alzheimer’s

Thursday, July 23, 2009

A puzzling finding for promising Alzheimer's drug

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

LA Times

Many researchers believe that one way to treat symptoms of Alzheimer's disease is with drugs that reduce a substance called beta amyloid. This is a protein that is the main constituent of plaques found in the brains of people with the disease.

But in a surprising finding presented Wednesday at the Alzheimer's Assn. 2009 International Conference in Vienna, researchers discovered that a promising medication in phase-3 testing in the United States, called dimebolin or Dimebon, actually increases beta amyloid in the brain in animal models.

"This result is highly unexpected in what may prove to be a clinically beneficial Alzheimer's drug," Dr. Samuel Gandy, the lead author of the study, said in a news release. "We need more research to further clarify how dimebolin affects beta amyloid levels in the brain."

Previous studies show that Dimebon, which was used for years in Russia as an antihistamine, appears to help people suffering from mild to moderate Alzheimer's disease symptoms. In June, enrollment was completed for a six-month pivotal trial of the medication. The manufacturer, Medivation Inc., has announced it hopes to file a new drug application for Dimebon in 2011.

Researchers can't explain why Dimebon appears to be helpful even though it increases beta amyloid. It could be the drug's beneficial powers have nothing to do with amyloid. This theory would point to a new avenue of drug targets for treating Alzheimer's disease.

In other news from the Alzheimer's meeting:


A large study of people with mild cognitive impairment showed that the combination of cognitive tests and brain scans can be used to predict the development of Alzheimer's disease.

Researchers at UC Berkeley studied 85 people with mild cognitive impairment. Those with low scores on a memory recall test and low glucose metabolism in a particular brain region (measured by PET scan) had a 15-times greater risk of developing Alzheimer's disease within two years of the study compared with the other participants.

"By the time a patient is diagnosed with Alzheimer's disease, there is usually little one can do to stop or reverse the decline," Dr. William Jagust, the principal investigator of the study, said in a news release. "Researchers are trying to determine whether treating patients before severe symptoms appear will be more effective, and that requires better diagnostic tools than what is currently available."


Several studies have found that middle-age people who have moderate alcohol intake, such as a glass of wine a day, receive some long-term protection against cognitive decline and dementia in old age. A new study, the largest and longest to examine regular alcohol intake on dementia in seniors, has found that this protection also applies in old age. But there is one important exception: People who already have mild cognitive impairment might fare worse if they drink alcohol.

The study examined 3,069 people ages 75 and older about their drinking habits. The participants were examined and interviewed every six months for six years. The study showed that in people with no cognitive impairment at the start of the study, drinking eight to 14 alcoholic beverages a week resulted in a 27% reduction in the risk of developing dementia compared with people who did not drink at all. But for older adults with mild cognitive impairment, any consumption of alcohol was linked to
------read all about promising Alzheimer's drug

Wednesday, July 22, 2009

Want to Live Forever? Antibiotic May Prevent Age-Related Disease in People

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Attorneyatlaw.com

Ever since Spanish explorer Juan Ponce de Leon set out for the New World to find the mythological Fountain of Youth, man has yearned to unlock the mysteries to staying forever young.


Now, 500 years after de Leon’s failed mission (he died in July 1521), medical researchers say an antibiotic pill designed to prevent organ transplant rejection has been shown to help laboratory mice live longer.

The drug, marketed under the brand name Rapamune but known generically as rapamycin or siroliumus, may also someday serve another purpose: Helping extend the lives of people battling age-related disease such as Alzheimer’s disease, cancer, heart disease, and other disorders, researchers said.

“Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of aging, or both,” David Harrison of The Jackson Laboratory in Bar Harbor, Maine and colleagues wrote in their report, published in the journal Nature, according to a Reuters news report.


Lab Rats Live Longer
In laboratory testing, adult female mice given Rapamycin lived 14 percent longer, while male mice given the drug lived nine percent longer lives, the researchers said.

However, people shouldn’t start taking Rapamycin pills daily in an effort to live longer lives, the research team cautioned. For one thing, mice in the experiment were not exposed to any infection, which could have significantly affected the study results. Also, mice do not tend to biologically age the same way as people and tend to live much shorter lives than humans.

Researchers across the United States gave.......read all about Antibiotic that prevents age related disease

Monday, July 20, 2009

Hypertrophy May Be the Key to Silent Alzheimer's Disease

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Modern Medicine

Neuronal hypertrophy more common in those with asymptomatic form of disease

(HealthDay News) -- The brain cells of people with asymptomatic Alzheimer's disease undergo significant hypertrophy, which may be a compensatory mechanism to prevent cognitive impairment, according to a study published online July 8 in Neurology.

Diego Iacono, M.D., of Johns Hopkins University in Baltimore, Md., and colleagues measured the volumes of neuronal cell bodies, nuclei and nucleoli in the CA1 region of the hippocampus of four groups of subjects: 10 with asymptomatic Alzheimer's disease, five with mild cognitive impairment, 10 with Alzheimer's disease, and 13 age-matched controls. They also compared the linguistic ability of all groups in early life.

Among the subjects with asymptomatic Alzheimer's disease, there were significantly greater degrees of hypertrophy compared to the subjects with mild cognitive impairment, at 44.9 percent more for cell bodies, 59.7 percent for nuclei, and 80.2 percent for nucleoli, the investigators found. Subjects in the control and asymptomatic Alzheimer's disease groups also had significantly higher idea density scores than their counterparts in the mild cognitive impairment and Alzheimer's disease groups.

"The major finding of the present study is the significant read all about Hypertrophy and Alzheimer's disease

Sunday, July 19, 2009

MicroRNAs Hold Promise For Treating Diseases In Blood Vessels

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

ScienceDaily-- A newly discovered mechanism controls whether muscle cells in blood vessels hasten the development of both atherosclerosis and Alzheimer's disease, according to an article published online July 5 in the journal Nature.

The study was led by the Gladstone Institute of Cardiovascular Disease (GICD) in San Francisco, with key contributions from the Aab Cardiovascular Research Institute at the University of Rochester School of Medicine and Dentistry.

Thanks to stem cells, humans develop from a single cell embryo into a complex being with about 250 unique cell types. As the fetus develops, cells divide and multiply (proliferate) in many generations and specialize (differentiate) with each generation until millions of functional cells result (bone, nerve, blood, skin, muscle, etc.). To serve specific roles in the body, some stem cells also switch back and forth between primitive, rapidly proliferating precursors and their mature, functioning, non-proliferating counterparts, a quality called "plasticity."

Among the most "plastic" of cells are vascular smooth muscle cells (VSMC), which form in layers around blood vessels, and by contracting or relaxing, regulate blood pressure. Because VSMC surround blood vessels that are continually becoming clogged by atherosclerosis, they must be ever ready to grow along with the vessel as it attempts, by growing, to remain open to blood flow despite fatty deposits and inflammation. If these efforts fail, heart attack or stoke may occur. Each time a vessel grows to avoid a clog, the VSMC surrounding it must grow too by reverting to their high-growth precursor form. Once a vessel reaches its growth limit, however, the growth that once kept vessels open begins adding to clogs by thickening vessel walls.

Past studies in Rochester have shown.........read all about MicroRNAs treating blood vessell diseases

Saturday, July 18, 2009

Middle-Aged Widows Have Highest Dementia Risk, Research Shows

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Bloomberg.com



By Chantal Britt

Bloomberg) -- People over 50 who suffer from negative emotions and disruption when they lose their partners have the highest risk of developing Alzheimer’s disease, according to a study published in the British Medical Journal.

Being widowed or divorced in mid-life carries three times the risk, while singles have double the risk of getting dementia than people who are married or cohabiting, according to a study from researchers in Sweden and Finland.

“Supportive intervention for individuals who have lost a partner might be a promising strategy in preventive health care,” lead researcher Krister Hakansson from Vaxjo University and the Karolinska Institute in Stockholm wrote in the study.

The number of dementia sufferers is forecast to increase to more than 80 million in 2040 from about 25 million in 2005, the researchers wrote. Higher education levels, physical exercise, mentally demanding work, top jobs and leisure and intellectual activities have been shown to protect against dementia, they said.

The researchers followed 1,449 people aged 65 to 79 years living in the Kuopio and Joensuu regions in eastern Finland for an average of 21 years to see whether their marital status affected the development of dementia later in life.

The dementia and Alzheimer’s disease risk increased if people lost their partners or got divorced, Hakansson found. The highest risk occurred in people who lost their partners or got divorced and also had a known genetic risk factor that’s associated with the development of Alzheimer’s disease.

These results add to a growing body of evidence that social factors may help sustain healthy brain functioning, Hakansson said. The development of cognitive impairment and dementia is a long process that’s affected by various factors throughout life, epidemiologist Catherine Helmer said in an editorial.

Research should now focus on..........read all of Middle-Aged Widows Have Highest Dementia Risk

Thursday, July 16, 2009

Research reveals how Alzheimer's spreads within the brain

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Sciencecentic.com

A research in mice has demonstrated how tangles of a so-called tau protein can spread within the brain. Tangled masses of that tau protein contribute to several neurodegenerative diseases - those that destroy brain functions - including Alzheimer's disease. The research has provided insights into how tau tangles spread that allow comparisons with the way prions, those that cause Creutzfeldt-Jakob Disease, destroy brain tissue.

Dr Michel Goedert of the Medical Research Council Laboratory of Molecular Biology in Cambridge contributed to the study alongside colleagues in Switzerland and Germany and the results are published today in the online edition of Nature Cell Biology.

Speaking about the study, Dr Goedert made it clear that it would be incorrect to suggest that Alzheimer's could be contagious: 'This research in mice does not show that tau pathology is contagious or that it can spread easily from mouse to mouse. What it has revealed is how tau tangles spread within brain tissues of individual mice. It suggests that tangles of proteins that build up in the brain to cause symptoms could have some contagious properties, within brain tissue but not between mice that haven't been injected with tissue from another mouse and certainly not between people. The work describes an experimental system that will allow scientists to study the mechanisms that underlie the transmission and spread of the tangles of tau proteins connected to the symptoms of Alzheimer's disease.'

Transgenic and wild-type mice were used in the study. Transgenic mice are genetically modified to carry specific genes. In this study the mice expressed the genes for the human versions of tau proteins.

The researchers injected brain tissue from mice modified to carry the gene for the form of human tau protein implicated in neurodegenerative disease into mice that carried the normal version of the human tau protein and therefore did not already have tangles in their brain tissue. They found that the injected material went on to create tangles of tau at the injection sites. Over time, the tau tangles then spread to neighbouring regions of the brain.

In another experiment, extract from the brains of mice with the gene for mutant-human-tau was injected into the brains of a wild-type mice. In comparison to the mice transgenic for human-tau, a smaller number of tau tangles developed where the tissue was injected and there was no evidence of the tau spreading throughout the brain.

Dr Goedert concluded: 'In contrast to prion diseases, human tauopathies like Alzheimer's are believed not....read all of how Alzheimer's spreads within the brain

Wednesday, July 15, 2009

DEMENTIA: MORE THAN JUST AN AGED CARE ISSUE

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

Australian Aging Agenda

Dementia is not just a concern for aged care providers but a pressing public health issue, according to the CEO of Alzheimer’s Australia.

Glenn Rees told a summit on Australia’s ageing population that dementia is a chronic condition that requires coordinated care planning.

The number of people with dementia is set to double by 2030 and without immediate government action, this could have serious effects on the health system.

Mr Rees told the forum that there should be a bigger focus on dementia in primary and acute care, noting that hospitals can be “dangerous” places for people with dementia.

“I believe there is a need to provide incentives through Medicare to promote timely and accurate diagnosis and ongoing support for people with dementia and their family carers,” he said.

“Australia should follow the lead of the UK National Healthcare Service in developing a five year strategy to train all GPs in dementia diagnosis and to support them with specialist services.”

Mr Rees praised the former government forlaunching the Dementia Initiative 2005, which led to the development of the EACH [Extended Aged Care at Home] Dementia packages.

But he reiterated the recommendations of last month’s Access Economics report, calling for more appropriate dementia respite services, revisions to the aged care planning process and quality standards for dementia ca
Turning to aged care staff interactions with people who have dementia, Mr Rees highlighted the importance of about.......aging care agenda

Tuesday, July 14, 2009

Great ideas, but what's the cost?

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia articles and activities,

PressRepublican.com

The American Association of Retired Persons, characteristically, has firm opinions on what should be included in any health-care-reform package Congress puts together. Typically, those opinions make great sense. But before this newspaper embraces AARP's suggestions, the matter of cost will have to be spelled out, which to date it hasn't.

AARP has six features it wants included in any legislation to be considered:

Extending Medicaid coverage to people between 50 and 64. Currently, a person must be 65 to qualify for coverage. This is the provision that causes most concern, since it seems to represent an enormous increase in cost.

However, Bill Ferris, legislative representative in AARP's New York State Legislative Office, explained the organization's justification in a meeting last week with the Press-Republican's Editorial Board this way: On a strictly humanitarian level, the coverage is essential so that all — or, at least, more — of the needy are taken care of. It is unacceptable that our humane, empathetic nation would leave so much of its population without access to medicine and health care. On a financial level, getting treatment for the now-uncovered needy leads to deep and expensive health problems by the time they reach their 65th birthday. Getting them treated early would relieve a lot of that cost.

He admits that the specific figures haven't been calculated yet, but that final reckoning has to figure prominently into any argument over extending Medicare coverage.

Closing a Medicaid coverage gap that now exists between annual drug costs of between $2,700 and $6,154. Below $2,700 and above $6,154, patients can receive subsidies. Between them, there is nothing. AARP wants the government close what is known as this non-coverage "doughnut hole."

Lowering drug costs through generic biologics. Biologic drugs, used against our most serious diseases, are also our most expensive. According to Ferris, the Food and Drug Administration now has no authority to grant approval for less-expensive generics.

Offering a follow-up care benefit to prevent costly hospital readmissions.

Developing a system of long-term care wherein patients are encouraged and enabled to live at home rather than in nursing homes.

Increasing availability of low-cost care, not just for the elderly but for low-income patients, as well — extending medical benefits to Medicaid recipients, of whom there are 28,000 in Clinton, Essex and Franklin counties now, according to Erin K. Mitchell, AARP associate state director.

AARP says some of the huge outlay of money could become.......read all of the Great ideas, but what's the cost
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info